In the context of human cancers where the BIM deletion allele predicts poorer therapeutic responses and clinical outcomes, such as in CML or EGFR-NSCLC, the splice-switching ASOs we have identified may be used in combination with appropriate TKIs to overcome the negative effects of the BIM deletion. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.